Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Orchard Therapeutics price target lowered to $17 from $26 at JPMorgan » 09:09
05/22/20
05/22
09:09
05/22/20
09:09
ORTX

Orchard Therapeutics

$9.62 /

+0.685 (+7.67%)

JPMorgan analyst Anupam…

JPMorgan analyst Anupam Rama lowered the firm's price target on Orchard Therapeutics to $17 from $26 and keeps an Overweight rating on the shares following the company's Q1 results. The analyst sees potential for Orchard to transition to commercial stage company by the end of 2020 and continues to see "broad potential" for the pipeline.

ShowHide Related Items >><<
ORTX Orchard Therapeutics
$9.62 /

+0.685 (+7.67%)

ORTX Orchard Therapeutics
$9.62 /

+0.685 (+7.67%)

09/17/19
Fly Intel: Top five analyst initiations
09/17/19
Guggenheim bullish on Orchard Therapeutics, initiates with a Buy
09/17/19 Guggenheim
Orchard Therapeutics initiated with a Buy at Guggenheim
09/05/19 Barclays
Orchard Therapeutics initiated with an Overweight at Barclays
ORTX Orchard Therapeutics
$9.62 /

+0.685 (+7.67%)

ORTX Orchard Therapeutics
$9.62 /

+0.685 (+7.67%)

Over a week ago
Hot Stocks
Orchard Therapeutics presents new data from OTL-203 study for MPS-I » 06:05
05/15/20
05/15
06:05
05/15/20
06:05
ORTX

Orchard Therapeutics

$9.49 /

+0.01 (+0.11%)

Orchard Therapeutics…

Orchard Therapeutics announced new interim data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-203, an ex vivo autologous hematopoietic stem cell gene therapy in development for the treatment of mucopolysaccharidosis type I at the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. "We have made strong progress with the MPS-I clinical trial and are pleased to see these interim results, with all patients achieving hematological recovery in less than 45 days - a primary outcome measure - as well as supraphysiological levels of IDUA enzyme in the blood. In addition, the trial results to date have shown promising preliminary clinical effects on motor skills, IQ and growth in the first two patients with 12 and 18 months of follow-up," said Maria Ester Bernardo, M.D., Ph.D., co-principal investigator at SR-Tiget. "We also observed reconstitution of enzyme activity in the cerebral spinal fluid in the first two treated patients with 12 months of follow-up, complemented by a decrease in glycosaminoglycan levels in the CSF. We look forward to continuing to assess the outcomes of this investigational gene therapy for patients with this often-fatal condition."

ShowHide Related Items >><<
ORTX Orchard Therapeutics
$9.49 /

+0.01 (+0.11%)

ORTX Orchard Therapeutics
$9.49 /

+0.01 (+0.11%)

09/17/19
Fly Intel: Top five analyst initiations
09/17/19
Guggenheim bullish on Orchard Therapeutics, initiates with a Buy
09/17/19 Guggenheim
Orchard Therapeutics initiated with a Buy at Guggenheim
09/05/19 Barclays
Orchard Therapeutics initiated with an Overweight at Barclays
ORTX Orchard Therapeutics
$9.49 /

+0.01 (+0.11%)

ORTX Orchard Therapeutics
$9.49 /

+0.01 (+0.11%)

Hot Stocks
Orchard Therapeutics announces upcoming milestones » 07:51
05/07/20
05/07
07:51
05/07/20
07:51
ORTX

Orchard Therapeutics

$11.92 /

+0.68 (+6.05%)

Metachromatic…

Metachromatic Leukodystrophy: Obtain approval in the EU for OTL-200 for the treatment of MLD in the second half of 2020 and launch in the first half of 2021. File an IND and seek RMAT designation in the U.S. for OTL-200 for the treatment of MLD in 2020, with the intention of submitting a BLA pending the resolution of FDA's feedback. Wiskott-Aldrich syndrome: Prepare for BLA and marketing authorization application regulatory filings in the U.S. and EU, respectively, for OTL-103 for the treatment of WAS in 2021. Mucopolysaccharidosis Type I: Report interim data from the proof-of-concept study of OTL-203 for the treatment of MPS-I in the second half of 2020. Report one-year follow-up results for OTL-203 for the treatment of MPS-I, including the primary endpoints, in the first half of 2021. Initiate a registrational study for OTL-203 for the treatment of MPS-I in 2021. Mucopolysaccharidosis Type IIIA: Enroll five patients and report interim data from the proof-of-concept study of OTL-201 for the treatment of MPS-IIIA in 2021

ShowHide Related Items >><<
ORTX Orchard Therapeutics
$11.92 /

+0.68 (+6.05%)

09/17/19
Fly Intel: Top five analyst initiations
09/17/19
Guggenheim bullish on Orchard Therapeutics, initiates with a Buy
09/17/19 Guggenheim
Orchard Therapeutics initiated with a Buy at Guggenheim
09/05/19 Barclays
Orchard Therapeutics initiated with an Overweight at Barclays
Earnings
Orchard Therapeutics reports Q1 EPS (51c), consensus (51c)  07:50
05/07/20
05/07
07:50
05/07/20
07:50
ORTX

Orchard Therapeutics

$11.92 /

+0.68 (+6.05%)

 
ShowHide Related Items >><<
ORTX Orchard Therapeutics
$11.92 /

+0.68 (+6.05%)

09/17/19
Fly Intel: Top five analyst initiations
09/17/19
Guggenheim bullish on Orchard Therapeutics, initiates with a Buy
09/17/19 Guggenheim
Orchard Therapeutics initiated with a Buy at Guggenheim
09/05/19 Barclays
Orchard Therapeutics initiated with an Overweight at Barclays
Hot Stocks
Orchard Therapeutics expects cash, investments to fund operations into 2022  07:50
05/07/20
05/07
07:50
05/07/20
07:50
ORTX

Orchard Therapeutics

$11.92 /

+0.68 (+6.05%)

 
ShowHide Related Items >><<
ORTX Orchard Therapeutics
$11.92 /

+0.68 (+6.05%)

09/17/19
Fly Intel: Top five analyst initiations
09/17/19
Guggenheim bullish on Orchard Therapeutics, initiates with a Buy
09/17/19 Guggenheim
Orchard Therapeutics initiated with a Buy at Guggenheim
09/05/19 Barclays
Orchard Therapeutics initiated with an Overweight at Barclays
Hot Stocks
Orchard Therapeutics announces new strategic plan, reduces headcount by 25% » 07:49
05/07/20
05/07
07:49
05/07/20
07:49
ORTX

Orchard Therapeutics

$11.92 /

+0.68 (+6.05%)

Core Elements of the New…

Core Elements of the New Strategic Plan: Prioritize portfolio investments to realize opportunities for high need, high value indications; Establish focused commercial model for diagnosis and treatment of patients globally; Invest in next-generation manufacturing technology and process innovations; Create operational efficiencies to maintain financial strength and flexibility. The company is announcing several key changes to its operations intended to support the new strategic plan. These include plans to: Establish MLD (OTL-200), WAS (OTL-103), MPS-I (OTL-203) and MPS-IIIA (OTL-201) programs as top near-term priorities and reduce investment in ADA-SCID (OTL-101) and TDT (OTL-300); Accelerate research in less rare indications, including two new programs in genetic subsets of frontotemporal dementia and Crohn's disease, announced today; Phase the commercial build to align with expected launch trajectories for OTL-200, which focuses primarily on the incidence-based opportunity, and OTL-103, which provides a significantly prevalence-based opportunity; and Focus manufacturing strategy by prioritizing investments in technology and process innovations, closing the company's California site, including the termination of the Fremont project and associated capital, and phasing investment in future manufacturing capacity.As a result of these decisions, the company has reduced its current headcount by approximately 25%. Collectively, all of the actions announced today are expected to achieve cash savings of approximately $125 million through the end of 2021, extending the company's existing cash runway into 2022. The company also provided an update on the progress of its U.S. biologics license application submission of OTL-200 for the treatment of MLD. The U.S. Food and Drug Administration recently provided written feedback on the sufficiency of the company's data package, including the clinical endpoints, natural history analysis and chemistry, and manufacturing and controls data. Orchard intends to use FDA's guidance to further analyze the latest available CMC and clinical data, file an investigational new drug application and seek Regenerative Medicine Advanced Therapy designation in 2020. The company believes this will facilitate a more comprehensive dialogue with the FDA to resolve open matters before the intended BLA submission.

ShowHide Related Items >><<
ORTX Orchard Therapeutics
$11.92 /

+0.68 (+6.05%)

09/17/19
Fly Intel: Top five analyst initiations
09/17/19
Guggenheim bullish on Orchard Therapeutics, initiates with a Buy
09/17/19 Guggenheim
Orchard Therapeutics initiated with a Buy at Guggenheim
09/05/19 Barclays
Orchard Therapeutics initiated with an Overweight at Barclays
Conference/Events
Orchard Therapeutics participates in a virtual bus tour with Piper Sandler » 16:10
05/03/20
05/03
16:10
05/03/20
16:10
ORTX

Orchard Therapeutics

$10.78 /

-0.47 (-4.18%)

Biotech Analyst Raymond…

Biotech Analyst Raymond holds a virtual bus tour with CEO Gaspar on May 7 at 4:15 pm. Webcast Link

ShowHide Related Items >><<
ORTX Orchard Therapeutics
$10.78 /

-0.47 (-4.18%)

09/17/19
Fly Intel: Top five analyst initiations
09/17/19
Guggenheim bullish on Orchard Therapeutics, initiates with a Buy
09/17/19 Guggenheim
Orchard Therapeutics initiated with a Buy at Guggenheim
09/05/19 Barclays
Orchard Therapeutics initiated with an Overweight at Barclays
Conference/Events
Orchard Therapeutics participates in a virtual bus tour with Piper Sandler » 15:03
05/03/20
05/03
15:03
05/03/20
15:03
ORTX

Orchard Therapeutics

$10.78 /

-0.47 (-4.18%)

Biotech Analyst Raymond…

Biotech Analyst Raymond holds a virtual bus tour with CEO Gaspar on May 7 at 4:15 pm. Webcast Link

ShowHide Related Items >><<
ORTX Orchard Therapeutics
$10.78 /

-0.47 (-4.18%)

09/17/19
Fly Intel: Top five analyst initiations
09/17/19
Guggenheim bullish on Orchard Therapeutics, initiates with a Buy
09/17/19 Guggenheim
Orchard Therapeutics initiated with a Buy at Guggenheim
09/05/19 Barclays
Orchard Therapeutics initiated with an Overweight at Barclays
Hot Stocks
Orchard Therapeutics announces eight presentations at ASGCT » 07:19
04/29/20
04/29
07:19
04/29/20
07:19
ORTX

Orchard Therapeutics

$11.75 /

+0.11 (+0.95%)

Orchard Therapeutics…

Orchard Therapeutics announced eight upcoming presentations from across its neurometabolic, primary immune deficiency and blood disorder franchises at the American Society of Gene & Cell Therapy 23rd Annual Meeting, which will take place online May 12-15, 2020, marking the company's most comprehensive presentation of clinical data at a medical meeting to date. Accepted abstracts include data on three investigational treatments to address various neurometabolic disorders, including mucopolysaccharidosis type I, with high unmet need. Of note, two of the eight presentations at ASGCT focus on new interim data from OTL-203, Orchard's investigational gene therapy for the treatment of MPS-I, a rare, inherited neurometabolic disease caused by a deficiency of the alpha-L-iduronidase lysosomal enzyme that results in the accumulation of complex carbohydrates called glycosaminoglycans and is characterized by neurological, skeletal and cardiovascular problems. The presentations also include the full integrated analysis of the registrational data set of OTL-101 for the treatment of adenosine deaminase severe combined immunodeficiency, which includes all patients treated in the U.S. with 24 months of follow-up; full results of the clinical proof-of-concept clinical trial for OTL-300 for the treatment of transfusion-dependent beta thalassemia, which achieved its primary outcome measures; and long-term outcomes in patients with ADA-SCID treated with Strimvelis.

ShowHide Related Items >><<
ORTX Orchard Therapeutics
$11.75 /

+0.11 (+0.95%)

09/17/19
Fly Intel: Top five analyst initiations
09/17/19
Guggenheim bullish on Orchard Therapeutics, initiates with a Buy
09/17/19 Guggenheim
Orchard Therapeutics initiated with a Buy at Guggenheim
09/05/19 Barclays
Orchard Therapeutics initiated with an Overweight at Barclays
Over a month ago
Hot Stocks
Orchard Therapeutics doses first patient with OTL-201 gene therapy in PoC trial » 07:27
04/27/20
04/27
07:27
04/27/20
07:27
ORTX

Orchard Therapeutics

$11.89 /

+0.6 (+5.31%)

Orchard Therapeutics…

Orchard Therapeutics announced that the first patient has been dosed in an open-label, proof-of-concept investigational study of OTL-201, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of mucopolysaccharidosis type IIIA. The study is designed to evaluate safety, tolerability and clinical efficacy and is intended to enroll up to five patients between three months and 24 months of age who will be followed for three years. The study also contains a number of key secondary outcome measures such as overall survival, cognition and behavior to help inform future clinical development of HSC gene therapy in this indication.

ShowHide Related Items >><<
ORTX Orchard Therapeutics
$11.89 /

+0.6 (+5.31%)

09/17/19
Fly Intel: Top five analyst initiations
09/17/19
Guggenheim bullish on Orchard Therapeutics, initiates with a Buy
09/17/19 Guggenheim
Orchard Therapeutics initiated with a Buy at Guggenheim
09/05/19 Barclays
Orchard Therapeutics initiated with an Overweight at Barclays

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.